Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

September 17, 2024 updated by: Yongchang Zhang, Hunan Province Tumor Hospital

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Study Overview

Status

Recruiting

Conditions

Non Small Cell Lung Cancer

Detailed Description

Inclusion criteria:

diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT

Study Type

Observational

Enrollment (Estimated)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Nong Yang, MD
Phone Number: +8613873123436 +8613055193557
Email: yangnong0217@163.com

Study Contact Backup

Name: Yongchang Zhang, MD
Phone Number: 7+861383123436 +8613873123436
Email: zhangyongchang@csu.edu.cn

Study Locations

China
- Hunan
  - Changsha, Hunan, China, 410013
    - Recruiting
    - Yongchang Zhang
    - Contact:
      
      Yongchang Zhang, MD
      
      Phone Number: +8613873123436 +8613873123436
      
      Email: zhangyongchang@csu.edu.cn

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Sampling Method

Probability Sample

Study Population

Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Description

Inclusion Criteria:

≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
Potentially Resectable NSCLC
Treatment Plan is Crizotinb or Standard Chemotherapy

Exclusion Criteria:

Patients with contraindication of chemotherapy
Pregnant or breast feeding women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PFS Time Frame: may 2020- may 2021 (1 year)	Progression free survival	may 2020- may 2021 (1 year)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
OS Time Frame: may 2020- may 2021 (1 year)	Overall survival	may 2020- may 2021 (1 year)
ORR Time Frame: may 2020- may 2021 (1 year)	To measure the patients's overall response rate	may 2020- may 2021 (1 year)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hunan Province Tumor Hospital

Investigators

Principal Investigator: YONGCHANG ZHANG, Hunan Cancer Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 24, 2020

Primary Completion (Estimated)

December 24, 2024

Study Completion (Estimated)

March 24, 2025

Study Registration Dates

First Submitted

March 25, 2020

First Submitted That Met QC Criteria